Takeda Pharmaceutical Company Limited (TYO:4502)
Japan · Delayed Price · Currency is JPY 5,118.00
-2.00 (-0.04%)
May 29, 2026, 3:30 PM JST
TYO:4502 Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 191,762 | 107,928 | 144,067 | 317,017 | 230,059 |
Depreciation & Amortization | 721,127 | 720,982 | 695,415 | 664,400 | 583,151 |
Other Amortization | - | 40,414 | 32,587 | - | - |
Loss (Gain) From Sale of Assets | -15,197 | -5,703 | -1,780 | -6,797 | -7,174 |
Asset Writedown & Restructuring Costs | 145,716 | 106,529 | 150,017 | 64,394 | 54,515 |
Loss (Gain) From Sale of Investments | 1,006 | -602 | 20,757 | 3,991 | -11,195 |
Loss (Gain) on Equity Investments | 2,177 | 3,986 | -6,473 | 8,630 | 15,367 |
Stock-Based Compensation | 72,775 | 72,867 | 70,871 | 60,672 | 43,374 |
Other Operating Activities | 124,704 | 70,153 | -133,114 | -109,887 | 116,403 |
Change in Accounts Receivable | -70,166 | -58,959 | 15,104 | 75,127 | 127,294 |
Change in Inventory | -61,293 | -34,973 | -115,743 | -79,155 | -46,148 |
Change in Accounts Payable | -3,150 | -7,118 | -9,895 | -84,804 | 125,157 |
Change in Other Net Operating Assets | -68,030 | 41,678 | -145,469 | 63,568 | -107,698 |
Operating Cash Flow | 1,041,431 | 1,057,182 | 716,344 | 977,156 | 1,123,105 |
Operating Cash Flow Growth | -1.49% | 47.58% | -26.69% | -13.00% | 11.10% |
Capital Expenditures | -176,003 | -200,795 | -175,420 | -140,657 | -123,252 |
Sale of Property, Plant & Equipment | 6,454 | 78 | 8,606 | 962 | 1,815 |
Cash Acquisitions | - | - | - | - | -49,672 |
Divestitures | 33,325 | 20,556 | 19,959 | 7,958 | 28,196 |
Sale (Purchase) of Intangibles | -234,930 | -147,046 | -305,310 | -493,032 | -62,785 |
Investment in Securities | -8,607 | -11,407 | 1,255 | 12,103 | 8,580 |
Other Investing Activities | 10,620 | -28,446 | -12,952 | 5,564 | -1,007 |
Investing Cash Flow | -369,141 | -367,060 | -463,862 | -607,102 | -198,125 |
Short-Term Debt Issued | - | 27,490 | 277,000 | 40,000 | - |
Long-Term Debt Issued | 586,060 | 1,024,460 | 100,000 | 75,000 | 249,334 |
Total Debt Issued | 586,060 | 1,051,950 | 377,000 | 115,000 | 249,334 |
Short-Term Debt Repaid | -341,780 | - | - | - | -2 |
Long-Term Debt Repaid | -243,204 | -1,366,264 | -375,487 | -400,071 | -849,809 |
Total Debt Repaid | -584,984 | -1,366,264 | -375,487 | -400,071 | -849,811 |
Net Debt Issued (Repaid) | 1,076 | -314,314 | 1,513 | -285,071 | -600,477 |
Repurchase of Common Stock | -51,603 | -51,860 | -2,326 | -26,929 | -77,531 |
Common Dividends Paid | -311,901 | -302,498 | -287,188 | -279,416 | -283,665 |
Other Financing Activities | -134,392 | -82,753 | -66,415 | -117,732 | -108,592 |
Financing Cash Flow | -496,820 | -751,425 | -354,416 | -709,148 | -1,070,265 |
Foreign Exchange Rate Adjustments | 34,472 | -11,385 | 26,204 | 22,929 | 28,758 |
Net Cash Flow | 209,942 | -72,688 | -75,730 | -316,165 | -116,527 |
Free Cash Flow | 865,428 | 856,387 | 540,924 | 836,499 | 999,853 |
Free Cash Flow Growth | 1.06% | 58.32% | -35.34% | -16.34% | 11.13% |
Free Cash Flow Margin | 19.21% | 18.69% | 12.69% | 20.77% | 28.02% |
Free Cash Flow Per Share | 539.95 | 533.47 | 342.28 | 532.85 | 633.95 |
Cash Interest Paid | 121,380 | 112,984 | 100,375 | 108,555 | 108,207 |
Cash Income Tax Paid | 172,562 | 150,413 | 202,039 | 185,966 | 140,423 |
Levered Free Cash Flow | 356,631 | 735,617 | 119,407 | 480,297 | 929,111 |
Unlevered Free Cash Flow | 438,631 | 817,171 | 191,527 | 553,405 | 1,005,631 |
Change in Working Capital | -202,639 | -59,372 | -256,003 | -25,264 | 98,605 |